ERBB2 and neoplasm: The requirement of tumor-targeted CD1d treatment to achieve a therapeutic effect was best demonstrated in the mice treated with the irrelevant αGC/sCD1d-anti-HER2 fusion protein, as all animals had fast tumor growth.